CJC-1295

Also known as: DAC-GRF, Drug Affinity Complex GHRH, CJC-1295 DAC

Evidence Tier Bhigh riskintermediatenot approved

Long-acting GHRH analogue studied in human trials for sustained GH/IGF-1 elevation.

FDA Safety Flag

The FDA has identified this substance as one that may present significant safety risks when used in compounding, including concerns about immunogenicity, impurity characterization, and/or insufficient safety information.

WADA S2

This substance falls under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). If you are subject to anti-doping rules, this category of substances is prohibited at all times.

GH Axis

This substance modulates the growth hormone axis. GH-axis stimulation carries risks including glucose intolerance, fluid retention, and theoretical concerns about sustained IGF-1 elevation.

Overview

CJC-1295 is a long-acting GHRH analogue designed to prolong exposure versus native GHRH. Human trials in healthy adults used subcutaneous microgram/kg dosing and showed sustained GH/IGF-1 elevations over days, with IGF-1 effects persisting up to ~2 weeks after single dosing. FDA has flagged CJC-1295 in its compounding safety risk context. Common adverse events include injection-site reactions, headache, diarrhea, flushing, and transient hypotension at higher doses.

Research Details

Mechanism of Action

Long-acting GHRH analogue that increases endogenous GH secretion and downstream IGF-1; designed to prolong exposure versus native GHRH.

Study Dose Range

Human trials: subcutaneous 30-60 Âµg/kg; sustained GH/IGF-1 elevations observed.

Administration Routes

subcutaneous

Onset / Timeline

Biomarker effects persist multiple days; IGF-1 elevations up to ~2 weeks after single dose.

Expected Effects

Sustained GH and IGF-1 elevation; body composition modulation (long-horizon, not well-established for consumer outcomes).

Adverse Effects

Injection-site reactions, headache, diarrhea, flushing, transient hypotension at higher doses.

Contraindications

GH-axis stimulation risks: glucose intolerance, theoretical neoplasia concerns with elevated IGF-1.

Interaction Notes

Monitor insulin/glucose sensitivity, thyroid axis, and cortisol/prolactin. Trials report no significant cortisol/prolactin/TSH/LH increases at 60 Âµg/kg single dose.

Related Goals

Muscle Growth & StrengthFat Loss & MetabolismGH Axis Optimization

Known Interactions

caution with Ipamorelin

GHRH analog + GHS-R agonist may produce additive GH release; multiple GH-axis peptides flagged for safety/characterization concerns.

caution with GHRP-6

Additive GH-axis stimulation plausible; FDA flags both compounds in compounding safety-risk context.

caution with GHRP-2

Additive GH-axis stimulation plausible (mechanistic); conservative gating.

caution with MK-677

Oral ghrelin-receptor agonism plus GHRH analog raises GH-axis complexity and glucose-monitoring burden.

Available From

Amino Club

consumer RUO · COA: product page COA viewer

blend product (CJC-1295 + ipamorelin, variant-dependent) · variant-dependent on product page

Consumer RUO; review product details carefully

Amino Club currently shows CJC in a CJC-IPA NO DAC blend rather than as a standalone CJC-1295 product, so compare that product carefully.

USVisit Vendor

QC: third-party purity testing; product-level COA on page

Shipping: US/ROW (verify current policy) · affiliate: public program

Frequently Compared

Sermorelin

GHRH(1-29) analogue that stimulates pulsatile GH secretion, historically used in clinical settings.

Tier B

Tesamorelin

FDA-approved GHRH analogue for HIV-associated lipodystrophy. Prescription only.

Tier A

Ipamorelin

Selective GHSR agonist profiled for more targeted GH release with less ACTH/cortisol spillover than earlier secretagogues.

Tier B-C

GHRP-2

GH secretagogue studied in human stimulation tests with documented endocrine spillover effects.

Tier B

Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.